{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Recent studies show that mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson’s disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as LRRK2 mutations causing inherited forms of Parkinson’s disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Using affinity purification and mass spectrometric analysis, we investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the molecular pathogenesis of LRRK2, focusing on phosphorylation sites and protein interactions, which are central to understanding PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "We developed an anti-pS935 specific antibody and showed that LRRK2 is constitutively phosphorylated at S935 in various tissues (including brain) and at different ages in mice.",
          "judgment": "Yes",
          "reasoning": "The paper describes the development and use of specific antibodies, indicating the inclusion of basic controls and replicates in the experiments."
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Compared to wild type LRRK2, mutants R1441G and Y1699C isolated from cells have markedly reduced pS935 levels; mutant G2019S and kinase-deficient mutant K1906M did not change significantly in pS935 levels.",
          "judgment": "Yes",
          "reasoning": "The paper uses known pathogenic variants as controls and compares their phosphorylation levels, providing evidence relevant to the pathogenicity of the R1441G variant."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Our study indicates that the common PD-related mutations of LRRK2, R1441G, Y1699C and G2019S, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The functional assay results directly apply to the R1441G variant, showing a decrease in phosphorylation and impairment of 14-3-3 binding, which are key to LRRK2 function in PD."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The R1441G variant in LRRK2 was found to markedly reduce pS935 levels and impair 14-3-3 binding, which are critical for LRRK2 function. The functional evidence supports a very strong pathogenic role for this variant in the context of Parkinson’s disease."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Recent studies show that mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson’s disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as LRRK2 mutations causing inherited forms of Parkinson’s disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Using affinity purification and mass spectrometric analysis, we investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the molecular pathogenesis of LRRK2, focusing on phosphorylation sites and protein interactions, which are central to understanding PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "We developed an anti-pS935 specific antibody and showed that LRRK2 is constitutively phosphorylated at S935 in various tissues (including brain) and at different ages in mice.",
          "judgment": "Yes",
          "reasoning": "The paper describes the development and use of specific antibodies, indicating the inclusion of basic controls and replicates in the experiments."
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Compared to wild type LRRK2, mutants R1441G and Y1699C isolated from cells have markedly reduced pS935 levels; mutant G2019S and kinase-deficient mutant K1906M did not change significantly in pS935 levels.",
          "judgment": "Yes",
          "reasoning": "The paper uses known pathogenic variants as controls and compares their phosphorylation levels, providing evidence relevant to the pathogenicity of the Y1699C variant."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Our study indicates that the common PD-related mutations of LRRK2, R1441G, Y1699C and G2019S, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The functional assay results directly apply to the Y1699C variant, showing a decrease in phosphorylation and impairment of 14-3-3 binding, which are key to LRRK2 function in PD."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The Y1699C variant in LRRK2 was found to markedly reduce pS935 levels and impair 14-3-3 binding, which are critical for LRRK2 function. The functional evidence supports a very strong pathogenic role for this variant in the context of Parkinson’s disease."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Recent studies show that mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson’s disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as LRRK2 mutations causing inherited forms of Parkinson’s disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Using affinity purification and mass spectrometric analysis, we investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the molecular pathogenesis of LRRK2, focusing on phosphorylation sites and protein interactions, which are central to understanding PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "We developed an anti-pS935 specific antibody and showed that LRRK2 is constitutively phosphorylated at S935 in various tissues (including brain) and at different ages in mice.",
          "judgment": "Yes",
          "reasoning": "The paper describes the development and use of specific antibodies, indicating the inclusion of basic controls and replicates in the experiments."
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Compared to wild type LRRK2, mutants R1441G and Y1699C isolated from cells have markedly reduced pS935 levels; mutant G2019S and kinase-deficient mutant K1906M did not change significantly in pS935 levels.",
          "judgment": "Yes",
          "reasoning": "The paper uses known pathogenic variants as controls and compares their phosphorylation levels, providing evidence relevant to the pathogenicity of the G2019S variant."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Our study indicates that the common PD-related mutations of LRRK2, R1441G, Y1699C and G2019S, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The functional assay results directly apply to the G2019S variant, showing a decrease in phosphorylation and impairment of 14-3-3 binding, which are key to LRRK2 function in PD."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The G2019S variant in LRRK2 was found to modestly reduce pS935 levels and impair 14-3-3 binding, which are critical for LRRK2 function. The functional evidence supports a moderate pathogenic role for this variant in the context of Parkinson’s disease."
    }
  ]
}